ITB-Med Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 42

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $140M

  • Investors
  • 3

ITB-Med General Information

Description

Developer of an immunomodulatory biologic designed for transplantation, autoimmunity, neurodegenerative diseases, and gene therapy. The company's monoclonal antibody allows the complete discontinuation of all immunosuppression treatments, enabling medical practitioners to provide immunosuppression freedom to their patients, potentially leading to better outcomes, improved quality of life, and reduced healthcare costs.

Contact Information

Website
www.itb-med.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 110 East 59th Street
  • Floor 28
  • New York, NY 10022
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Vertical(s)
Corporate Office
  • 110 East 59th Street
  • Floor 28
  • New York, NY 10022
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ITB-Med Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 01-Oct-2022 $140M Completed Generating Revenue
1. Early Stage VC 03-Apr-2018 Completed Generating Revenue
To view ITB-Med’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

ITB-Med Patents

ITB-Med Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026175970-A1 Anti-cd2 antibody treatment in kidney transplantation Pending 19-Feb-2025
US-20240285756-A1 Method and composition for inducing tolerance Inactive 07-Sep-2021
US-20240101671-A1 Method and composition for inducing tolerance Pending 25-Jan-2021
US-20230365687-A1 Anti-cd2 antibodies Active 23-Jun-2020
US-12661399-B2 Method of treating an immune-related disorder or disease associated with an organ or tissue transplant with a combination of an anti-cd2 antibody and a ctla-4 co-stimulation blockade Active 23-Jun-2020 A61K39/3955
To view ITB-Med’s complete patent history, request access »

ITB-Med Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ITB-Med Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
GG 1978 Venture Capital Minority
Yaya Capital Venture Capital Minority
Angel (individual) Minority
To view ITB-Med’s complete investors history, request access »

ITB-Med FAQs

  • When was ITB-Med founded?

    ITB-Med was founded in 2016.

  • Where is ITB-Med headquartered?

    ITB-Med is headquartered in New York, NY.

  • What is the size of ITB-Med?

    ITB-Med has 42 total employees.

  • What industry is ITB-Med in?

    ITB-Med’s primary industry is Biotechnology.

  • Is ITB-Med a private or public company?

    ITB-Med is a Private company.

  • What is ITB-Med’s current revenue?

    The current revenue for ITB-Med is .

  • How much funding has ITB-Med raised over time?

    ITB-Med has raised $207M.

  • Who are ITB-Med’s investors?

    GG 1978, Yaya Capital, and have invested in ITB-Med.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process